Finch Therapeutics Group (FNCH) Competitors $14.15 -0.10 (-0.70%) As of 02:01 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsInsider TradesOwnershipSEC FilingsTrendsBuy This Stock FNCH vs. DBVT, CRDL, SLS, ZURA, ACOG, ANL, TCRX, CLYM, VIGL, and VTGNShould you be buying Finch Therapeutics Group stock or one of its competitors? The main competitors of Finch Therapeutics Group include DBV Technologies (DBVT), Cardiol Therapeutics (CRDL), SELLAS Life Sciences Group (SLS), Zura Bio (ZURA), Alpha Cognition (ACOG), Adlai Nortye (ANL), TScan Therapeutics (TCRX), Climb Bio (CLYM), Vigil Neuroscience (VIGL), and Vistagen Therapeutics (VTGN). These companies are all part of the "pharmaceutical products" industry. Finch Therapeutics Group vs. DBV Technologies Cardiol Therapeutics SELLAS Life Sciences Group Zura Bio Alpha Cognition Adlai Nortye TScan Therapeutics Climb Bio Vigil Neuroscience Vistagen Therapeutics DBV Technologies (NASDAQ:DBVT) and Finch Therapeutics Group (NASDAQ:FNCH) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, community ranking, media sentiment, profitability, analyst recommendations, risk, institutional ownership and dividends. Do insiders and institutionals hold more shares of DBVT or FNCH? 71.7% of DBV Technologies shares are owned by institutional investors. Comparatively, 21.8% of Finch Therapeutics Group shares are owned by institutional investors. 1.9% of DBV Technologies shares are owned by company insiders. Comparatively, 44.9% of Finch Therapeutics Group shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Does the MarketBeat Community believe in DBVT or FNCH? DBV Technologies received 395 more outperform votes than Finch Therapeutics Group when rated by MarketBeat users. Likewise, 54.36% of users gave DBV Technologies an outperform vote while only 52.63% of users gave Finch Therapeutics Group an outperform vote. CompanyUnderperformOutperformDBV TechnologiesOutperform Votes40554.36% Underperform Votes34045.64% Finch Therapeutics GroupOutperform Votes1052.63% Underperform Votes947.37% Which has more risk and volatility, DBVT or FNCH? DBV Technologies has a beta of -0.09, suggesting that its stock price is 109% less volatile than the S&P 500. Comparatively, Finch Therapeutics Group has a beta of 1.21, suggesting that its stock price is 21% more volatile than the S&P 500. Does the media refer more to DBVT or FNCH? In the previous week, DBV Technologies had 3 more articles in the media than Finch Therapeutics Group. MarketBeat recorded 4 mentions for DBV Technologies and 1 mentions for Finch Therapeutics Group. DBV Technologies' average media sentiment score of 0.15 beat Finch Therapeutics Group's score of 0.00 indicating that DBV Technologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DBV Technologies 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Finch Therapeutics Group 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts prefer DBVT or FNCH? DBV Technologies presently has a consensus target price of $22.50, suggesting a potential upside of 186.26%. Given DBV Technologies' stronger consensus rating and higher possible upside, research analysts clearly believe DBV Technologies is more favorable than Finch Therapeutics Group.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score DBV Technologies 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Finch Therapeutics Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is DBVT or FNCH more profitable? Finch Therapeutics Group has a net margin of 0.00% compared to DBV Technologies' net margin of -815.73%. Finch Therapeutics Group's return on equity of -69.14% beat DBV Technologies' return on equity.Company Net Margins Return on Equity Return on Assets DBV Technologies-815.73% -106.07% -76.17% Finch Therapeutics Group N/A -69.14%-26.92% Which has better valuation & earnings, DBVT or FNCH? DBV Technologies has higher revenue and earnings than Finch Therapeutics Group. DBV Technologies is trading at a lower price-to-earnings ratio than Finch Therapeutics Group, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDBV Technologies$15.73M10.28-$72.73M-$4.50-1.75Finch Therapeutics Group$110K206.59-$74.75M-$8.82-1.60 SummaryDBV Technologies beats Finch Therapeutics Group on 11 of the 18 factors compared between the two stocks. Remove Ads Get Finch Therapeutics Group News Delivered to You Automatically Sign up to receive the latest news and ratings for FNCH and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FNCH vs. The Competition Export to ExcelMetricFinch Therapeutics GroupBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$22.73M$2.96B$5.55B$7.49BDividend YieldN/A1.53%5.35%4.04%P/E Ratio-1.6030.3922.9618.07Price / Sales206.59383.42361.6786.81Price / CashN/A168.6838.1634.64Price / Book0.993.636.493.99Net Income-$74.75M-$72.06M$3.21B$247.18M7 Day Performance-1.05%-10.45%-6.27%-6.41%1 Month Performance-5.98%-16.67%-0.55%-7.42%1 Year Performance499.58%-30.52%6.15%-4.30% Finch Therapeutics Group Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FNCHFinch Therapeutics GroupN/A$14.15-0.7%N/A+467.7%$22.73M$110,000.00-1.60190DBVTDBV Technologies3.0967 of 5 stars$4.35-2.6%$22.50+417.8%+0.7%$89.37M$15.73M-0.9780CRDLCardiol Therapeutics2.6447 of 5 stars$1.08-3.6%$8.40+677.8%-49.1%$89.05MN/A-2.7620Earnings ReportUpcoming EarningsGap DownSLSSELLAS Life Sciences Group0.0773 of 5 stars$1.28+3.7%N/A-7.6%$88.89M$1M-1.8310ZURAZura Bio2.1122 of 5 stars$1.43+6.0%$15.80+1,004.1%-60.1%$88.80MN/A0.003Analyst ForecastGap DownACOGAlpha Cognition1.7986 of 5 stars$5.47+2.6%$20.00+265.6%N/A$87.63MN/A-2.14N/AEarnings ReportAnalyst ForecastAnalyst RevisionNews CoverageGap UpANLAdlai Nortye2.4346 of 5 stars$2.35+0.9%$9.00+283.0%-78.1%$86.72M$5M0.00127Gap UpTCRXTScan Therapeutics3.5492 of 5 stars$1.54-3.8%$9.33+506.5%-82.4%$86.30M$2.82M-1.44100Short Interest ↓Gap DownCLYMClimb Bio2.901 of 5 stars$1.27-3.8%$10.00+687.4%N/A$85.37MN/A-0.609Gap DownVIGLVigil Neuroscience3.8943 of 5 stars$1.82-4.1%$16.25+791.9%-46.8%$84.94MN/A-0.8840News CoverageGap DownVTGNVistagen Therapeutics1.1133 of 5 stars$2.91+0.1%N/A-55.7%$84.28M$698,000.00-1.9740Gap Down Remove Ads Related Companies and Tools Related Companies DBVT Alternatives CRDL Alternatives SLS Alternatives ZURA Alternatives ACOG Alternatives ANL Alternatives TCRX Alternatives CLYM Alternatives VIGL Alternatives VTGN Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:FNCH) was last updated on 4/3/2025 by MarketBeat.com Staff From Our Partners“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredNew “Trump” currency proposed in DCAfter a massive run-up – tech stocks are crashing. And as you’d suspect, the rich and powerful got out firs...Paradigm Press | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Finch Therapeutics Group, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Finch Therapeutics Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy FNCH Stock Free FNCH Stock Alerts